| API | Indication | Micronised | CEP | EU DMF | US DMF | JP DMF | KR DMF | CN DMF |
|---|---|---|---|---|---|---|---|---|
| Abediterol | Asthma and COPD | |||||||
| Aclidinium bromide | COPD | |||||||
| Batefenterol | COPD | |||||||
| Brexpiprazole | Schizophrenia and major depressive disorders | |||||||
| Brivaracetam | Antiepileptic | |||||||
| Clomethiazole | Insomnia | • | ||||||
| Crisaborole p | Atopic dermatitis and psoriasis | |||||||
| Imidafenacin p | Urinary incontinence | |||||||
| Luliconazole p | Antifungal | |||||||
| Olodaterol p | COPD | • | ||||||
| Revefenacin | COPD | |||||||
| Rivaroxaban p | Thrombosis. Stroke | • | ||||||
| Salbutamol / Albuterol sulfate | Asthma and COPD | |||||||
| Tolvaptan | Hiponatremia | |||||||
| Umeclidinium bromide | COPD | • | ||||||
| Vilanterol trifenatate | Asthma and COPD |
P = Patent applications/granted patents owned by Neuraxpharm
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / INKE. All rights reserved.